NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹69 Cr | ₹41 Cr | ₹6.32 Cr | ₹6.24 Cr | ₹8.06 Cr |
What is the latest Total Non-Current Liabilities ratio of NGL FINECHEM ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹69 Cr |
| Mar2025 | ₹41 Cr |
| Mar2024 | ₹6.32 Cr |
| Mar2023 | ₹6.24 Cr |
| Mar2022 | ₹8.06 Cr |
How is Total Non-Current Liabilities of NGL FINECHEM Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹69 Cr | 67.27 | |
| Mar2025 | ₹41 Cr | 549.52 | |
| Mar2024 | ₹6.32 Cr | 1.27 | |
| Mar2023 | ₹6.24 Cr | -22.60 | |
| Mar2022 | ₹8.06 Cr | - | |
Compare Total Non-Current Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,611.7 Cr | -1.7% | -4.8% | 76.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹422,991.0 Cr | 1.1% | -4.2% | 4.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹256,310.0 Cr | 7.5% | 1.3% | 45.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹173,604.0 Cr | 1.8% | -6.3% | 26.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,722.0 Cr | 9.3% | 9.5% | 4.3% | Stock Analytics | |
| CIPLA | ₹109,628.0 Cr | 1.5% | -2.3% | -17.3% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -1.7% |
-4.8% |
76.3% |
| SENSEX | 1.2% |
0.4% |
-12.2% |
You may also like the below Video Courses